Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma: a Single-Center Experience From Southern Turkey

Utku Aygüneş; Ali Bulent Antmen

doi:10.31067/acusaglik.1478940

Research Article

BibTex

RIS

Cite

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma: a Single-Center Experience From Southern Turkey

Year 2024, Volume: 15 Issue: 4, 334 - 341, 01.10.2024

Utku Aygüneş , Ali Bulent Antmen

https://doi.org/10.31067/acusaglik.1478940

https://izlik.org/JA68AA73UG

Abstract

Purpose: Non‑Hodgkin lymphoma (NHL) accounts for 8‑10% of all childhood cancers. In this study, we aimed to describe the epidemiological and clinical characteristics and treatment outcomes of pediatric NHL patients treated at a tertiary center.
Methods: The oncologic records of the patients diagnosed and followed up as NHL between 2013 and 2023 were reviewed retrospectively.
Results: A total of 36 patients were enrolled in this study. The most common pathologic subtype was lymphoblastic lymphoma (LL) (n=21, 58.3%) followed by Burkitt lymphoma (BL) (n=10, 27.8%), diffuse large B-cell non-Hodgkin lymphoma (DLBCL) (11.1%, n=4), and anaplastic large cell lymphoma (ALCL) (2.8%, n=1). Overall survival (OS) and event-free survival (EFS) were significantly longer in patients without bone marrow (BM) involvement (p=0.001 and p=0.02, respectively). EFS was significantly longer in patients without central nervous system (CNS) involvement (p=0.038). OS and EFS did not differ significantly according to NHL subtypes (p>0.05). There was no significant difference in OS according to age groups (p=0.7).
Conclusion: The OS with NHL has significantly improved. With the development of effective treatment regimens based on various pathologic subtypes, the result of pediatric NHL has significantly improved in recent years. The survival rates have reached >90%.

Keywords

cancer , pediatric , non-Hodgkin Lymphoma

Ethical Statement

This study was approved by the Ethical Committee for Acibadem University, with the assigned decision no: 2024-6/233 and date: 18.04.2024.

References

1. Kutluk T, Yeşilipek A. Pediatric Cancer Registry in Turkey 2009-2021 (TPOG & TPHD). JCO 2022;40:e22020. https://doi.org/10.1200/JCO.2022.40.16_suppl.e22020
2. Karalexi MA, Georgakis MK, Dessypris N, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. 2017 Dec;35(4):608-618. doi: 10.1002/hon.2347. 3. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 473-83.
4. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. Erratum in: Leukemia. 2023 Sep;37(9):1944-1951.
5. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010 Jun;102(3):83-7.
6. Britto TI, Fattah SA, Rahman MAU, Chowdhury MAU. A Systematic Review on Childhood Non-Hodgkin Lymphoma: An Overlooked Phenomenon in the Health and Research Sector of Bangladesh. Cureus. 2023 Sep 25;15(9):e45937. doi: 10.7759/cureus.45937.
7. Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol. 2006;45(3):258-71. doi: 10.1080/02841860500531682. PMID: 16644568.
8. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA; EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009 Apr;45(6):992-1005. doi: 10.1016/j.ejca.2008.11.042. Epub 2009 Feb 21. PMID: 19231160.
9. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 473.
10. Kara B, Uğraş S, Ertan K, Köksal Y. Evaluation of clinical features, treatment approaches and treatment outcomes of children with non-Hodgkin lymphoma. J Contemp Med. November 2022;12(6):989-996. doi:10.16899/jcm.1202662
11. Setty BA, Termuhlen AM. Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep. 2010 Jul;5(3):163-8. doi: 10.1007/s11899-010-0055-9. PMID: 20490722.
12. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 474.
13. Derqaoui S, Boujida I, Marbouh O, Rouas L, Hessissen L, Lamalmi N. Non Hodgkin Lymphoma Among Children: Pathological Aspects and Diagnostic Challenges. Clin Pathol. 2022 Apr 17;15:2632010X221090156. doi: 10.1177/2632010X221090156.
14. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 479.
15. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 476-477.
16. Karadoğan M, Demirsoy U, Anık YA, Aksu MG, Çorapçıoğlu F. Pediatric Non-Hodgkin Lymphoma: Ten-Year Experience with Berlin-Frankfurt-Munster (BFM) Protocols from a Tertiary Care Hospital in Turkey. Acta Med Nicomedia. Şubat 2023;6(1):49-54. doi:10.53446/actamednicomedia.1164931
17. Sherief LM, Elsafy UR, Abdelkhalek ER, Kamal NM, Youssef DM, Elbehedy R. Disease patterns of pediatric non-Hodgkin lymphoma: A study from a developing area in Egypt. Mol Clin Oncol. 2015 Jan;3(1):139-144. doi: 10.3892/mco.2014.425. Epub 2014 Sep 24.
18. Burkhardt B, Zimmermann M, Oschlies I, et al. BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005 Oct;131(1):39-49. doi: 10.1111/j.1365-2141.2005.05735.x.
19. Özdemir GN, Öz Ş, Tahtakesen Güçer TN, et al. Hodgkin dışı lenfomalı çocukların klinik özellikleri ve tedavi sonuçları. LLM Dergi 2024;8(1):27-38.
20. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007 Sep 1;25(25):3915-22. doi: 10.1200/JCO.2007.11.0700.
21. Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatr Blood Cancer. 2019 Sep;66(9):e27873. doi: 10.1002/pbc.27873. Epub 2019 Jun 17.
22. Burkhardt B, Taj M, Garnier N, et al. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers (Basel). 2021 Apr 25;13(9):2075. doi: 10.3390/cancers13092075.
23. Naik S, Martinez CA, Omer B, et al. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 Sep 24;3(18):2689-2695. doi: 10.1182/bloodadvances.2018026203.
24. Suh JK, Gao YJ, Tang JY, et al. Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia. Cancer Res Treat. 2020 Apr;52(2):359-368. doi: 10.4143/crt.2019.219. Epub 2019 Jul 29.
25. Ostojska M, Nowak E, Twardowska J, Lejman M, Zawitkowska J. CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma. J Pers Med. 2023 Nov 10;13(11):1595. doi: 10.3390/jpm13111595.
26. Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019 Aug 27;3(16):2491-2498. doi: 10.1182/bloodadvances.2019000025.